Remote care platform developer Conversa increased its total funding to more than $26m in a round co-led by Northwell Ventures and backed by UH Ventures.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

AstraZeneca and Fresenius Medical Care will exit the kidney disease treatment developer in a $725m acquisition that could potentially rise to $2.1bn.

Novo co-led the series C round with Longitude Capital and Checkmate will use the cash to advance clinical development of its lead asset, which is targeting melanoma.

Based on research at University of Adelaide, Royal Adelaide Hospital and Johns Hopkins's Hospital, Glyscend is working on a pill to treat type 2 diabetes.

UCeed will target four to eight healthcare projects with a focus on child medicine, investing up to $220,000 per transaction.

Francisco Partners has injected $30m into Kyruus, five months after the patient-matching platform developer received $42m in a series D round featuring Salesforce and Providence St Joseph.

Life sciences venture firm 4Bio Capital has secured the biopharmaceutical company as the first strategic backer for its second fund.

Solvay Ventures veteran Alexandre Ouimet-Storrs has joined Mercia alumna Nicola Broughton to form a medical cannabis-focused investment firm.

GCV Rising Star David Schulte has taken up a senior vice-president role to oversee McKesson’s strategic investment arm, after previous unit head Tom Rodgers ascended to chief strategy officer.